Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Pulmonary hypertension (PH) is a progressive and potentially dangerous, life-threatening disease. A variety of different diseases can be associated with a pathological increase in the average pulmonary artery pressure, hence PH is a very diverse entity. The pathophysiology of PH is extremely variabl...
Main Authors: | N. A. Tsareva, S. N. Avdeev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2016-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/72 |
Similar Items
-
A case of combined treatment of severe chronic thromboembolic pulmonary hypertension
by: R. S. Akchurin, et al.
Published: (2015-12-01) -
Chronic thromboembolic pulmonary hypertension: approaches to diagnosis and treatment
by: N. A. Shostak, et al.
Published: (2013-12-01) -
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01) -
Current approaches to management of patients with pulmonary hypertension
by: S. N. Avdeev
Published: (2014-12-01) -
The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
by: S. E. Gratsianskaya, et al.
Published: (2020-10-01)